An Approach to Measuring Somatic Mosaicism in Solid Tissues

Why It Matters

Widespread driver mutations in histologically normal tissue reveal a hidden pool of pre‑cancerous clones, offering new avenues for early detection and preventive interventions in age‑related cancers.

Key Takeaways

• scG2P enables single‑cell mosaicism profiling in solid tissue
• Over 50% of esophageal cells carry driver mutations
• NOTCH1 mutations dominate, driving clonal overgrowth
• TP53 clones show increased division and impaired maturation
• Findings link age‑related mosaicism to pre‑cancerous states

Pulse Analysis

Somatic mosaicism—where genetically distinct cells coexist within a tissue—has emerged as a hallmark of human aging, yet quantifying it in solid organs has remained technically daunting. Traditional bulk sequencing masks low‑frequency clones, while single‑cell approaches have been limited to blood, where cells are readily isolated. The inability to capture both genotype and phenotype at the single‑cell level in solid tissue has constrained insights into how mosaic mutations influence tissue function and disease progression.

The advent of single‑cell Genotype‑to‑Phenotype sequencing (scG2P) changes that landscape. By simultaneously reading DNA mutations and corresponding gene‑expression profiles from individual cells, scG2P revealed that more than half of the 10,000+ esophageal cells examined harbored clonal driver mutations. NOTCH1 emerged as the dominant altered gene, steering cells toward unchecked expansion by impairing normal differentiation pathways. TP53‑mutant clones, though less frequent, displayed heightened proliferative activity and disrupted maturation, echoing early steps of tumorigenesis. These findings illustrate that even morphologically normal epithelium can house extensive pre‑cancerous clonal architecture.

Clinically, mapping somatic mosaicism in situ offers a predictive lens for age‑related cancer risk. Detecting driver‑mutant clones before overt pathology could enable surveillance strategies tailored to an individual’s mutational burden. Moreover, the scG2P framework is adaptable to other solid tissues, paving the way for broader atlases of mosaicism across the body. As researchers integrate these data with longitudinal health records, the prospect of intervening at the earliest molecular signs of malignancy becomes increasingly tangible, potentially reshaping preventive oncology.